Inhibrx Biosciences Inc. (INBX)
NASDAQ: INBX
· Real-Time Price · USD
23.44
-0.50 (-2.09%)
At close: Aug 15, 2025, 3:59 PM
23.33
-0.47%
After-hours: Aug 15, 2025, 04:34 PM EDT
Inhibrx Biosciences Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -28.65M | -43.31M | -47.87M | -14.43M | 1.83B | -78.71M | -93.6M | -51.79M | -47.05M | -48.92M | -40.91M | -35.33M | -37.73M | -31.25M | -21.19M | -20.58M | -20.71M | -19.29M |
Depreciation & Amortization | 661K | 675K | 689K | 761K | 475K | 360K | 298K | 304K | 294K | 295K | 302K | 309K | 307K | 307K | 307K | 299K | 298K | 291K |
Stock-Based Compensation | 2.77M | 2.45M | 2.98M | 2.96M | 47.53M | 6.4M | 6.43M | 6.53M | 6.25M | 4.69M | 5.36M | 4.69M | 5.3M | 5.11M | 4.18M | 3.49M | 3.95M | 3.42M |
Other Working Capital | n/a | 3.47M | 2.42M | 9.55M | 18.07M | 3.76M | 25.89M | -119K | -30K | -855K | 2.96M | -1.01M | -511K | -743K | -735K | -508K | -818K | 387K |
Other Non-Cash Items | -4.73M | 967K | 470K | 23.11M | -1.97B | 1.71M | 6.26M | 1.68M | 1.65M | 1.63M | 1.68M | 1.44M | 1.06M | 902K | 786K | 776K | 602K | 563K |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | -4.56M | 1K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -9K | n/a |
Change in Working Capital | n/a | 3.32M | 4K | -42.69M | 35.49M | 7.2M | 28.36M | -10.97M | -3.45M | 1.42M | 2.98M | -1.95M | 4.14M | -2M | -6.71M | 2.34M | -6.51M | -6.63M |
Operating Cash Flow | -29.95M | -35.9M | -43.72M | -30.28M | -57.36M | -63.05M | -56.82M | -54.24M | -42.3M | -39.94M | -30.6M | -30.84M | -26.92M | -26.94M | -22.62M | -13.68M | -22.38M | -21.65M |
Capital Expenditures | n/a | -21K | -16K | -247K | -1.22M | -1.12M | -3.44M | -811K | -317K | -23K | -267K | 20K | -322K | -117K | -267K | -169K | -414K | -14K |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 55K | n/a |
Investing Cash Flow | n/a | -21K | -16K | -247K | -1.22M | -1.12M | -3.44M | -811K | -317K | -23K | -267K | 20K | -322K | -117K | -267K | -169K | -359K | -14K |
Debt Repayment | n/a | 99.97M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | n/a | -125K | 32.95M | 2.71M | n/a | n/a | 860K | 199.89M | 854K | 356K | 158.66M | 506K | 60.16M | 39.22M | 41.48M | 820K | 40.48M | 988K |
Financial Cash Flow | n/a | 99.84M | n/a | 2.71M | 32.95M | 38.73M | 860K | 199.89M | 854K | 356K | 158.66M | 506K | 60.16M | 39.22M | 41.48M | 820K | 40.48M | 988K |
Net Cash Flow | -29.95M | 63.92M | -43.74M | -30.53M | -25.62M | -25.44M | -59.4M | 144.84M | -41.76M | -39.61M | 127.79M | -30.31M | 32.92M | 12.17M | 18.6M | -13.02M | 17.74M | -20.67M |
Free Cash Flow | -29.95M | -35.92M | -43.74M | -30.53M | -58.57M | -64.17M | -60.26M | -55.06M | -42.62M | -39.97M | -30.87M | -30.82M | -27.24M | -27.06M | -22.89M | -13.84M | -22.79M | -21.66M |